Location of Repository

Oncolytic Viruses: Therapeutics With an Identity Crisis

By Caroline J. Breitbach, Brian D. Lichty and John C. Bell

Abstract

Oncolytic viruses (OV) are replicating viral therapeutics for the treatment of cancer and have been in laboratory development for about twenty years. Recently, the FDA approved Imlygic, a herpes virus based therapeutic for the treatment of melanoma and thus OVs have entered a new era where they are a weapon in the armament of the oncologist. OVs are unique therapeutics with multiple mechanisms of therapeutic activity. The exact path for their development and eventual uptake by pharmaceutical companies is somewhat clouded by an uncertain identity. Are they vaccines, tumour lysing therapeutics, inducers of innate immunity, gene therapy vectors, anti-vascular agents or all of the above? Should they be developed as stand-alone loco-regional therapeutics, systemically delivered tumour hunters or immune modulators best tested as combination therapeutics? We summarize data here supporting the idea, depending upon the virus, that OVs can be any or all of these things. Pursuing a “one-size fits all” approach is counter-productive to their clinical development and instead as a field we should build on the strengths of individual virus platforms

Topics: Oncolytic virus, Oncolytic immunotherapy, In situ vaccine, Immune checkpoint inhibitors, Medicine, R
Publisher: Elsevier
Year: 2016
DOI identifier: 10.1016/j.ebiom.2016.06.046
OAI identifier: oai:doaj.org/article:42e863292aa24425882e793163e59abb
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://doaj.org/toc/2352-3964 (external link)
  • http://www.sciencedirect.com/s... (external link)
  • https://doaj.org/article/42e86... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.